ADMA Biologics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

7. SEGMENTS (Tables)

7. SEGMENTS (Tables)

3 Months Ended

Mar. 31, 2015

Segment Reporting [Abstract]

Summarized financial information concerning reportable segments is shown in the following table:

		Plasma
Three Months Ended		Collection				Research and
March 31, 2015		Center				Development				Corporate				Consolidated

Revenues		$	1,484,217			$	-			$	18,889			$	1,503,106

Cost of product revenue			909,629				-				-				909,629

Gross profit			574,588				-				18,889				593,477

Loss from operations			(473,506	)			(1,401,723	)			(1,327,108	)			(3,202,337	)

Other expense			-				-				(403,198	)			(403,198	)

Net loss			(473,506	)			(1,401,723	)			(1,730,306	)			(3,605,535	)

Property and equipment, net			2,592,473				-				145,289				2,737,762

Depreciation and
amortization expense			104,917				-				12,205				117,122

			Plasma
Three Months Ended			Collection				Research and
March 31, 2014			Center				Development				Corporate				Consolidated

Revenues		$	1,541,670			$	-			$	18,889			$	1,560,559

Cost of product revenue			977,030				-				-				977,030

Gross profit			564,640				-				18,889				583,529

Loss from operations			(237,829	)			(4,330,457	)			(1,115,700	)			(5,683,986	)

Other expense			(1,730	)			-				(218,156	)			(219,886	)

Net loss			(239,559	)			(4,330,457	)			(1,333,856	)			(5,903,872	)

Property and equipment, net			655,342				1,920				171,686				828,948

Depreciation and
amortization expense			35,983				809				11,507				48,299